Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix

Thrombosis and Haemostasis

Volumn 90, Issue 5, 2003, Pages 921-929

  Van Hensbergen, Yvette ^a   Broxterman, Henk J ^a   Peters, Erna ^b   Rana, Sareena ^a   Elderkamp, Yvonne W ^a   Van Hinsbergh, Victor W M ^b,c   Koolwijk, Pieter ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Bestatin; CD13; Fibrin; u PAR

Indexed keywords

ACTINONIN; AMASTATIN; AMINOPEPTIDASE; ANTIBODY; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BESTATIN; ENZYME INHIBITOR; FIBRIN; MICROSOMAL AMINOPEPTIDASE; MY 7 ANTIBODY; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN; WM15 ANTIBODY;

ANGIOGENESIS; ARTICLE; CELL INVASION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR; VASCULAR ENDOTHELIUM;

EID: 0242521663     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-03-0144     Document Type: Article

References (36)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
2. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
3. Van Hinsbergh VW, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: In vitro studies with human endothelial cells. EXS 1997; 79: 391-411.
4. Koolwijk P, Van Erck MG, De Vree WJ, et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177-88.
5. Pepper MS, Belin D, Montesano R, et al. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111: 743-55.
6. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vas Biol 2001; 21: 1104-17.
7. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44.
8. Andolfo A, English WR, Resnati M, et al. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 2002; 88: 298-306.
9. Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: Implication for angiogenesis in fibrin matrices. Blood 2001; 97: 3123-31.
10. Collen A, Hanemaaijer R, Lupu F, et al. Membrane-type matrix metalloproteinase mediated angiogenesis in a fibrin-collagen matrix. Blood 2003; 101: 1810-7.
11. Hiraoka N, Allen E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysis. Cell 1998; 95: 365-77.
12. Lafleur MA, Handsley MM, Knauper V, et al. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002; 115: 3427-38.
13. Umezawa H, Aoyagi T, Suda H, et al. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 1976; 29: 97-9.
14. Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Current Drug Metabolism 2002; 2: 67-85.
15. Ota K. Review of ubenimex (Bestatin): Clinical research. Biomed Pharmacother 1991; 45: 55-60.
16. Ota K, Uzuka Y. Clinical trials of bestatin for leukemia and solid tumors. Biotherapy 1992; 4: 205-14.
17. Bhagwat SV, Lahdenranta J, Giordano R, et al. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001; 97: 652-9.
18. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-7.
19. Bhagwat SV, Petrovic N, Okamoto Y, et al. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 2003; 101: 1818-26.
20. Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology 2002; 122: 376-86.
21. Van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 2002; 8: 3747-54.
22. Van Hinsbergh VWM, Draijer R. Culture and Characterization of Human Endothelial Cells. In: Oxford University Press. Shaw AJ 1996; 87-110.
23. Favaloro EJ. CD-13 ('gp150'; aminopeptidase-N): Co-expression on endothelial and haemopoietic cells with conservation of functional activity. Immunol Cell Biol 1991; 69: 253-60.
24. Van Hensbergen Y, Broxterman HJ, Elderkamp YW, et al. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol 2002; 63: 897-908.
25. Xu Y, Lai LT, Gabrilove JL, et al. Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res 1998; 4: 171-6.
26. Gao B, Saba TM, Tsan MF. Role of alpha(v)beta(3)-integrin in TNF-alpha-induced endothelial cell migration. Am J Physiol Cell Physiol 2002; 283: 1196-1205.
27. Rüegg C, Dormond O, Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: Which side to target? Endothelium 2002; 9: 151-60.
28. Kroon ME, Koolwijk P, Van Goor H, et al. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 1999; 154: 1731-42.
29. Van Hinsbergh VW, Van Den Berg EA, Fiers W, et al. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-8.
30. Emeis JJ, Verheijen JH, Ronday HK, et al. Progress in clinical fibrinolysis. Fibrinolysis Proteolysis 1997; 11: 67-84.
31. Takeuchi T, Harris JL, Huang W, et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
32. Ichinose A, Fujikawa J, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
33. Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60: 6196-6200.
34. Collen A, Maas A, Kooistra T, et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened A alpha-chain, alters endothelial capillary tube formation. Blood 2001; 97: 973-80.
35. Collen A, Koolwijk P, Kroon ME, et al. Influence of fibrin structure on the formation and maintenance of capillary-like tubules by human microvascular endothelial cells. Angiogenesis 1998; 2: 153-65.
36. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.